CD300A and neoplasm: However, since CD300a is abundantly expressed in various immune cells, it is challenging to define the contribution of CD300a as a tumor progression mediator, making it difficult to conclusively define the therapeutic benefit of CD300a blockade in cancer immunotherapy.